Apotek Produktion och Laboratorier AB (APL), one of the largest manufacturers of compounded medicines and a leading Contract Development and Manufacturing Organization (CDMO) in Sweden, announces its first delivery of a compounded medicine produced by 3D-printing technology. APL applies 3D-printing technology within the concept ExtempoPrint.
Erik Haeffler, CEO at APL, said, “We are pleased to have reached this important milestone for ExtempoPrint. ExtempoPrint is an exciting model that suits compounding well. It enhances our abilitiy to fulfill APL's public policy assignment and creates new opportunities to meet patient needs.”
ExtempoPrint initially serves as an alternative to manual capsule filling, a common manufacturing method for compounded medicines. With ExtempoPrint, APL can demonstrate improved process reliability, high dosing accuracy and improved protection for personnel. The technology is particularly valuable for low dose products where precision is essential.
The first compounded medicine is a medication used to treat high blood pressure (hypertension) intended for pediatric use. The target patient group is children undergoing cancer treatment, in whom hypertension may occur.
APL is co-operating on this technology with CurifyLabs, a Finnish health tech company. The printers are part of CurifyLabs' Compounding System Solution, which is already in use at several hospital pharmacies around Europe.
“APL has demonstrated strong capabilities in pharmacy compounding and we are pleased to see the introduction of our Compounding System Solution as part of ExtempoPrint. We look forward to combining our strengths to create even greater value for patients in need of personalized medicines,” said Charlotta Topelius, Chief Executive Officer at CurifyLabs.
APL will gradually introduce additional formulations through ExtempoPrint, based on suitability and demand.
About APL
Apotek Produktion & Laboratorier (APL) is one of Europe’s leading companies in the manufacture of extemporaneous medicines and stock preparations. They work on behalf of society and other pharmaceutical companies to create the greatest possible benefit for patients. Their vision is to make a difference for patients with special needs.
APL is also an established contract manufacturer within the life science industry, providing development and analytical services. With approximately 600 employees and five manufacturing units in Malmö, Gothenburg, Stockholm, Strängnäs, and Umeå, they develop medicines that improve and save lives.